Skip Navigation

Human Molecular Genetics 2006 15(Review Issue 1):R75-R79; doi:10.1093/hmg/ddl061
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dupuy, A. J.
Right arrow Articles by Copeland, N. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dupuy, A. J.
Right arrow Articles by Copeland, N. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sleeping beauty: a novel cancer gene discovery tool

Adam J. Dupuy, Nancy A. Jenkins and Neal G. Copeland*

Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA

* To whom correspondence should be addressed. Tel: +1 3018461260; Fax: +1 3018466666; Email: copeland{at}ncifcrf.gov

Received February 1, 2006; Revised March 2, 2006; Accepted March 10, 2006

The National Cancer Institute and the National Human Genome Research Institute recently announced a 3-year 100-million-dollar pilot study to use large-scale resequencing of genes in human tumors to identify new cancer genes. The hope is that some of these genes can be used as drug targets for developing better therapeutics for treating cancer. Although this effort will identify new cancer genes, it could be made more efficient by preferentially resequencing genes identified as novel candidate cancer genes in animal models of cancer. Although retroviral insertional mutagenesis has proven to be an effective tool for identifying novel cancer genes in the mouse, these studies are limited by the fact that retroviral mutagenesis primarily induces hematopoietic and mammary cancer, but little else, while the majority of cancers affecting humans are solid tumors. Recently, two groups have shown that sleeping beauty (SB) transposon-based insertional mutagenesis can also identify novel candidate cancer genes in the mouse. Unlike retroviral infection, SB transposition can be controlled to mutagenize any target tissue and thus potentially induce many different kinds of cancer, including solid tumors. SB transposition in animal models of cancer could therefore greatly facilitate the identification of novel human cancer genes and the development of better cancer therapies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. Sauvageau, M. Miller, S. Lemieux, J. Lessard, J. Hebert, and G. Sauvageau
Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia
Blood, January 15, 2008; 111(2): 790 - 799.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
A. J. Dupuy
Cancer Gene Discovery Using the Sleeping Beauty Transposon
Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 221 - 224.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Feschotte
The piggyBac transposon holds promise for human gene therapy
PNAS, October 10, 2006; 103(41): 14981 - 14982.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.